A Case of Steroid Refractory Acute GVHD Treated with IL-2 & TNF-α Blocker in a Myelodysplastic Syndrome Patient who Underwent Unrelated Allogeneic Stem Cell Transplantation

Hak Hyun Lee(Hanyang University), Chan Keum Park(Hanyang University), Young Yeol Lee(Hanyang University), Myung‐Ju Ahn(Sungkyunkwan University), Duk Joo Lee(Hanyang University), Won Sohn(Kangbuk Samsung Hospital), Chi Un Choi(Hanyang University), Jung Hye Choi(Hanyang University Guri Hospital), Myung Hee Chang(Hanyang University), Song Ree Park(Hanyang University), In Soon Kim(Hanyang University), Yoo Hum Baek(Hanyang University)
The Korean Journal of Hematology
January 1, 2006
10.5045/kjh.2006.41.1.51
Cited by 0

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537